Published in Pediatr Res on November 01, 1997
Obstruction of extrahepatic bile ducts by lymphocytes is regulated by IFN-gamma in experimental biliary atresia. J Clin Invest (2004) 2.40
Role of interferon in homologous and heterologous rotavirus infection in the intestines and extraintestinal organs of suckling mice. J Virol (2008) 1.28
Aetiology of biliary atresia: what is actually known? Orphanet J Rare Dis (2013) 1.18
Biliary atresia: recent progress. J Clin Gastroenterol (2008) 1.13
Variation in antagonism of the interferon response to rotavirus NSP1 results in differential infectivity in mouse embryonic fibroblasts. J Virol (2009) 1.13
Rotavirus and reovirus modulation of the interferon response. J Interferon Cytokine Res (2009) 1.11
Biliary atresia. Semin Immunopathol (2009) 1.05
Roles of VP4 and NSP1 in determining the distinctive replication capacities of simian rotavirus RRV and bovine rotavirus UK in the mouse biliary tract. J Virol (2010) 0.94
Loss of interleukin-12 modifies the pro-inflammatory response but does not prevent duct obstruction in experimental biliary atresia. BMC Gastroenterol (2006) 0.94
Biliary atresia. Orphanet J Rare Dis (2006) 0.92
Swiss outcomes in biliary atresia: are there lessons to be learned? J Pediatr Gastroenterol Nutr (2008) 0.77
The Sea Lamprey as an Etiological Model for Biliary Atresia. Biomed Res Int (2015) 0.77
New aspects in a murine model for extrahepatic biliary atresia. J Pediatr Surg (1997) 1.66
Role of interferon in natural kill of HSV-1-infected fibroblasts. J Immunol (1982) 1.22
Expression of leptin and leptin receptor isoforms in the human stomach. Gut (2000) 1.22
Emergence and decay of the human Mx homolog in cancer patients during and after interferon-alpha therapy. J Biol Response Mod (1990) 1.14
Human gamma interferon production by leukocytes induced with monoclonal antibodies recognizing T cells. J Immunol (1981) 1.12
Metastatic malignant ameloblastoma responding to chemotherapy with paclitaxel and carboplatin. Ann Oncol (2001) 1.06
Clinical significance of anti-IFN-alpha antibody titres during interferon therapy. Lancet (1987) 1.04
Progress in developing animal models for biliary atresia. Eur J Pediatr Surg (1998) 1.01
Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology (2000) 0.88
Leucocyte-derived interferon-alpha in patients with antibodies to recombinant IFN-alpha 2b. Lancet (1988) 0.85
Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther (2008) 0.84
[Distant metastasis of renal cell carcinomas to the head-neck area]. Laryngorhinootologie (1996) 0.84
[Exacerbation of psoriasis during alpha-interferon therapy]. Dtsch Med Wochenschr (1989) 0.83
[Quality of life in patients with remitting-relapsing multiple sclerosis in Germany]. Nervenarzt (2003) 0.82
Prevalence of sperm bound antibodies in infertile men with varicocele: the effect of varicocele ligation on antibody levels and semen response. J Urol (1994) 0.82
Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol (1989) 0.82
Characterization of interleukin 2-dependent cytotoxic T-cell clones. IV. Production of alpha, beta and gamma interferons and interleukin 2 by Lyt-2+ T cells. Cell Immunol (1983) 0.82
Production of interferon in the murine mixed lymphocyte culture. II. Interferon production is a T cell-dependent function, independent of proliferation. Eur J Immunol (1979) 0.81
Intracellular staining of Mx proteins in cells from peripheral blood, bone marrow and skin. Mol Pathol (1997) 0.80
True aneurysms of the palmar arch of the hand: a report of two cases. Microsurgery (1996) 0.80
Poststenotic cavitating pneumonia due to Rhodococcus equi in HIV infection. AIDS (1996) 0.79
Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b. Blut (1988) 0.78
Interferons in the treatment of multiple myeloma. J Clin Oncol (1990) 0.78
Induction of human gamma-interferon in lymphoid cells by Staphylococcus enterotoxin B; partial purification. J Interferon Res (1982) 0.78
No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol (1995) 0.77
Epitopes recognized by neutralizing therapy-induced human anti-interferon-alpha antibodies are localized within the N-terminal functional domain of recombinant interferon-alpha 2. Eur J Immunol (1996) 0.77
[Blood and serum values of Goettingen miniature swine. 2. Effect of endogenous and exogenous factors on the concentration of lipids, proteins and protein metabolites]. Zentralbl Veterinarmed A (1982) 0.77
Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo. J Immunother (1997) 0.76
Common variable immunodeficiency (CVID) and MxA-protein expression in blood leucocytes. Clin Exp Immunol (1995) 0.76
Expression of interferon-inducible Mx-proteins in patients with IgA nephropathy or Henoch-Schönlein purpura. Am J Kidney Dis (1999) 0.76
Correlation of the antiproliferative effect and the Mx-homologous protein induction by IFN in patients with malignant melanoma. J Invest Dermatol (1990) 0.76
Low dose alpha interferon treatment in chronic hepatitis B virus infection. Gut (1993) 0.76
[Diagnosis and therapy of lymphoid tumors of the orbits]. HNO (1997) 0.76
[Beta interferon therapy in hairy cell leukemia]. Klin Wochenschr (1987) 0.75
[EEG changes caused by gamma-interferon]. Dtsch Med Wochenschr (1986) 0.75
[Effect of interferon therapy on the function of the peripheral blood granulocytes in patients with malignant diseases]. Beitr Infusionther Klin Ernahr (1987) 0.75
Hemangioendothelioma of the mandible in a newborn infant - diagnostic and treatment approach of a rare vascular tumor. Oral Oncol (2001) 0.75
Two forms of ribose-phosphate isomerase in extracts from pig heart muscle [proceedings]. Arch Int Physiol Biochim (1978) 0.75
[Interferons--a new treatment principle in oncology?]. Fortschr Med (1988) 0.75
Ia dependent lymphokine production in the syngeneic mixed lymphocyte response. Behring Inst Mitt (1983) 0.75
[Unexpected fertilization results following insemination of hogs with disperm]. Dtsch Tierarztl Wochenschr (1977) 0.75
[Multicenter prospective controlled study of therapy of chronic myeloid leukemia. Comparison of busulfan, hydroxyurea and interferon alpha (April 1990 status)]. Onkologie (1991) 0.75
[Therapeutic procedure in hairy cell leukemia]. Klin Wochenschr (1987) 0.75
[The social network of families of HIV infected patients]. Z Psychosom Med Psychoanal (1992) 0.75
[Death caused by neglect?]. Arch Kriminol (2000) 0.75
Quantitation of interferon-induced Mx protein in whole blood lysates by an immunochemiluminescent assay: elimination of protease activity of cell lysates in toto. J Immunol Methods (1994) 0.75
Factors inhibiting IFN activity. Biotherapy (1996) 0.75
[Therapy of chronic myeloid leukemia with interferon-alpha. A decade of experiences]. Med Klin (Munich) (1996) 0.75
[Oral manifestations of Lpngerhans' cell histiocytosis. Therapeutic strategies involving oral and maxillofacial surgery]. Mund Kiefer Gesichtschir (1999) 0.75
[Rare differential diagnosis of breast tumor. Giant cell tumor of the ribs]. Langenbecks Arch Chir (1997) 0.75
Immunogenicity of different types of interferons in the treatment of hairy-cell leukemia. N Engl J Med (1988) 0.75
[Blood and serum values of Göttingen miniature swine. 7. Consideration of genetic parameters in research design]. Zentralbl Veterinarmed A (1988) 0.75
[The demonstration of microcalcification in breast core biopsies: DIMA specimen radiography (7x) compared to the histopathological findings]. Rofo (1999) 0.75
[Low-dose alpha-interferon treatment of hairy cell leukemia]. Klin Wochenschr (1987) 0.75
[Treatment of chronic hepatitis B with interferon alpha-2b]. Dtsch Med Wochenschr (1990) 0.75